Since the GLP-1R and NPY2R differ with respect to their tissue distribution and signaling properties, a dual agonist peptide such as EP45 might constitute an ideal medicinal agent with which to simultaneously treat T2DM and obesity. Here, NPY2R is linked to obesity due to melanocortin 4 receptor deficiency.